Agilon Health (AGL) Expected to Announce Earnings on Wednesday

Agilon Health (NYSE:AGL) will likely be posting its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect Agilon Health to post earnings of ($0.27) per share and revenue of $1.4614 billion for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, February 25, 2026 at 4:30 PM ET.

Agilon Health Stock Down 1.9%

Shares of Agilon Health stock opened at $0.35 on Wednesday. Agilon Health has a 52-week low of $0.34 and a 52-week high of $6.08. The firm’s 50 day moving average price is $0.75 and its 200-day moving average price is $0.88. The company has a market cap of $146.90 million, a P/E ratio of -0.47 and a beta of 0.06.

Hedge Funds Weigh In On Agilon Health

Hedge funds and other institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC grew its stake in Agilon Health by 243.3% during the 1st quarter. AQR Capital Management LLC now owns 501,440 shares of the company’s stock valued at $2,171,000 after acquiring an additional 355,365 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Agilon Health by 3.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 214,200 shares of the company’s stock valued at $927,000 after purchasing an additional 7,209 shares in the last quarter. Dynamic Technology Lab Private Ltd grew its position in shares of Agilon Health by 28.4% in the first quarter. Dynamic Technology Lab Private Ltd now owns 47,111 shares of the company’s stock valued at $204,000 after purchasing an additional 10,424 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in Agilon Health by 6.6% during the first quarter. Goldman Sachs Group Inc. now owns 5,060,333 shares of the company’s stock worth $21,911,000 after buying an additional 311,158 shares in the last quarter. Finally, Creative Planning lifted its position in Agilon Health by 17.6% during the second quarter. Creative Planning now owns 170,969 shares of the company’s stock worth $393,000 after buying an additional 25,548 shares in the last quarter.

Analyst Ratings Changes

Several research firms have weighed in on AGL. Royal Bank Of Canada upgraded Agilon Health from a “hold” rating to a “moderate buy” rating in a research note on Wednesday, December 3rd. Wells Fargo & Company dropped their target price on Agilon Health from $1.50 to $1.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of Agilon Health in a research report on Wednesday, January 21st. Barclays decreased their price objective on shares of Agilon Health from $1.50 to $1.00 and set an “underweight” rating for the company in a research note on Thursday, November 6th. Finally, Zacks Research upgraded shares of Agilon Health from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 21st. Four equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $2.71.

Key Stories Impacting Agilon Health

Here are the key news stories impacting Agilon Health this week:

• Neutral Sentiment: Management will participate in upcoming investor events (Cowen Health Care Conference March 2 — webcast on the IR site — and Jefferies summit). This provides a near‑term opportunity for management to address investor questions and could supply fresh guidance/clarity. Read More.
• Negative Sentiment: Multiple law firms have filed or announced investigations and are soliciting lead plaintiffs in a securities‑fraud class action covering purchases between Feb. 26, 2025 and Aug. 4, 2025; many notices highlight a March 2, 2026 lead‑plaintiff deadline. These announcements increase the likelihood of litigation, potential legal costs, and management distraction—key reasons for downward pressure on the stock. Representative notices:
  Read More.,
  Read More.,
  Read More.,
  Read More.,
  Read More.,
  Read More.,
  Read More.,
  Read More.,
  Read More.,
  Read More.,
  Read More..

Agilon Health Company Profile

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.